Treatment for Type-2-Diabetes News: Fixed Combination of DPP-4 and SGLT-2 Inhibitors

被引：0
|
作者：
不详
机构：
来源：
DIABETES STOFFWECHSEL UND HERZ | 2018年 / 27卷 / 03期
关键词：
TYPE-2; DIABETES-MELLITUS; MILLION PEOPLE; SITAGLIPTIN; THERAPY; RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [41] Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?
    Ahren, Bo
    CURRENT DIABETES REPORTS, 2011, 11 (02) : 83 - 90
  • [42] The safety of dipeptidyl peptidase-4 ( DPP-4) inhibitors or sodium- glucose cotransporter 2 ( SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta- analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Lopuch, Sylwia
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (04) : 269 - 283
  • [43] Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
    Young Sang Lyu
    Seok Oh
    Jin Hwa Kim
    Sang Yong Kim
    Myung Ho Jeong
    Cardiovascular Diabetology, 22
  • [44] Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?
    Bo Ahrén
    Current Diabetes Reports, 2011, 11 : 83 - 90
  • [45] Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
    Cho, Y. K.
    Kang, Y. M.
    Lee, S. E.
    Lee, J.
    Park, J. -Y.
    Lee, W. J.
    Kim, Y. -J.
    Jung, C. H.
    DIABETES & METABOLISM, 2018, 44 (05) : 393 - 401
  • [46] Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients?
    Strojek, Krzysztof
    Gorska, Juta
    Rokicka, Dominika
    Szymborska-Kajanek, Aleksandra
    Wrobel, Marta
    Sedek, Lukasz
    Szczepanski, Tomasz
    ENDOKRYNOLOGIA POLSKA, 2014, 65 (02) : 78 - 82
  • [47] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Liakos, Charalampos I.
    Papadopoulos, Dimitrios P.
    Sanidas, Elias A.
    Markou, Maria I.
    Hatziagelaki, Erifili E.
    Grassos, Charalampos A.
    Velliou, Maria L.
    Barbetseas, John D.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (02) : 123 - 137
  • [48] Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus
    Suzuki, Yuta
    Tanaka, Akihiro
    Tanaka, Mamoru
    Hidaka, Noriaki
    Miyake, Teruki
    Matsuura, Bunzo
    Hiasa, Yoichi
    Araki, Hiroaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (09) : 474 - 477
  • [49] SGLT-2 inhibition with canagliflozin: A new option for the treatment of type 2 diabetes
    Seufert, J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S52 - S58
  • [50] SAFETY AND EFFICACY OF DPP-4 INHIBITORS FOR THE MANAGEMENT OF HOSPITALIZED GENERAL MEDICINE AND SURGERY PATIENTS WITH TYPE 2 DIABETES
    Lorenzo-Gonzalez, Cristina
    Atienza-Sanchez, Elena
    Reyes-Umpierrez, David
    Vellanki, Priyathama
    Davis, Georgia M.
    Pasquel, Francisco J.
    Cardona, Saumeth
    Fayfman, Maya
    Peng, Limin
    Umpierrez, Guillermo E.
    ENDOCRINE PRACTICE, 2020, 26 (07) : 722 - 728
12345